About DRG Epidemiology
DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validate investments and identify growth opportunities in your markets of interest.
All of our epidemiological data, methods and insight are distributed via DRG’s Insights Platform, allowing the user to easily navigate between world regions and patient populations, as well as download epidemiological forecast data into an MS Excel format for offline use.
All epidemiological forecasts may be supplemented with custom deliverables, such as:
- Chart reviews or more granular stratification using DRG’s in-house real world datasets or physician survey data
- Customized and interactive patient flow models or additional subpopulations or metrics
- Expanded geographical coverage or extended forecast periods beyond those available
Our robust patient population sizing data includes therapeutic coverage of 140+ indications and 3400+ patient subpopulations, including extensive oncology subpopulation data by stage, line of therapy, and biomarker, as well as continually expanding niche and rare disease coverage.
The geographic breadth of data includes mature market (G7) reporting for all 140+ indications, as well as 90% global population coverage for the high-profile diseases, and expanded penetration for emerging and rest-of-world markets in select indications.
For over 20 years, our data and methodology have been developed and refined by DRG’s Epidemiology team of industry-leading subject matter experts, driven by rigorous methodology to uncover the impact of exposure, risk, and treatment, in addition to historical trends and age and gender cohorts.
All of our epidemiological forecasts are accompanied by a transparent description of our methods and data sources, the details of our systematic review underlying each forecast and associated summary evidence tables, and access to the authoring epidemiologist.
- Asia Pacific Data
- Key Findings
- Diagnosed Prevalence of Cystic Fibrosis per 1,000 People of All Ages in 2017 and 2027
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Cystic Fibrosis over the Next Ten Years
- Number of Additional Prevalent Cases of Cystic Fibrosis Incurred over 2017-2027 in the Countries Under Study
- Epidemiology Data
- Diagnosed Incident Cases of Cystic Fibrosis at Birth
- Diagnosed Prevalent Cases of Cystic Fibrosis
- Reference Materials
- Literature Review
- Risk/Protective Factors
Author(s): Alison Isherwood, MSc, MRes, PhD; Ruchika Sharma, MPH
Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.
Ruchika Sharma joined Decision Resources Group as Associate Epidemiologist in May 2016. She performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. She produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. She holds a Master of Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research, and a Bachelor of Dental Surgery from MN DAV Dental College & has previously worked as a dental surgeon and as a Fellow at the National Health Systems Resource Centre, where she supported the preparation of National Health Accounts - Guidelines for India 2016.